| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/BMT.2016.295 |
| P698 | PubMed publication ID | 27892952 |
| P2093 | author name string | S Lee | |
| H-J Kim | |||
| J-H Lee | |||
| K-H Lee | |||
| J-H Yoon | |||
| J-W Lee | |||
| D-Y Kim | |||
| Y-J Kim | |||
| S-H Shin | |||
| B-S Cho | |||
| K-S Eom | |||
| S-A Yahng | |||
| S-E Lee | |||
| W-S Min | |||
| Y-W Jeon | |||
| C-K Min | |||
| Y-S Choi | |||
| P2860 | cites work | The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Q22299206 |
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 | ||
| Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT | Q24685958 | ||
| Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study | Q28301602 | ||
| International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 | ||
| Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. | Q30353404 | ||
| Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System | Q33380307 | ||
| Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. | Q33772415 | ||
| Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome | Q33813439 | ||
| In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. | Q33997187 | ||
| National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 | ||
| Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome | Q34612644 | ||
| Revised international prognostic scoring system for myelodysplastic syndromes | Q34639717 | ||
| Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden | Q34919228 | ||
| Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. | Q35835657 | ||
| Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. | Q36339459 | ||
| Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome | Q36683757 | ||
| Myelodysplastic syndromes: the complexity of stem-cell diseases | Q36717910 | ||
| Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation | Q36763834 | ||
| Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure | Q36877036 | ||
| New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge | Q36920348 | ||
| Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes | Q36984304 | ||
| The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome | Q37175619 | ||
| Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome | Q37688233 | ||
| Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries | Q37737483 | ||
| Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review | Q37937818 | ||
| Are hypomethylating agents replacing induction-type chemotherapy before allogeneic stem cell transplantation in patients with myelodysplastic syndrome? | Q38223860 | ||
| 1994 Consensus Conference on Acute GVHD Grading | Q39513397 | ||
| Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes | Q39527812 | ||
| Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the | Q39708265 | ||
| Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies | Q40494657 | ||
| Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. | Q43249096 | ||
| Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure | Q43467909 | ||
| Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia | Q43628597 | ||
| Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. | Q44836524 | ||
| 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. | Q45960014 | ||
| Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. | Q46845322 | ||
| Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. | Q51815934 | ||
| Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. | Q53094779 | ||
| Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. | Q53121505 | ||
| Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation. | Q53218343 | ||
| Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. | Q53532028 | ||
| Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation | Q58416346 | ||
| Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia | Q58865927 | ||
| Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes | Q80768443 | ||
| WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) | Q81322446 | ||
| Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype | Q81769874 | ||
| Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia | Q82236404 | ||
| A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia | Q84730070 | ||
| Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms | Q85942967 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 522-531 | |
| P577 | publication date | 2016-11-28 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome | |
| P478 | volume | 52 |
| Q39205101 | Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. |
| Q45756342 | Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. |
Search more.